Wall Street brokerages forecast that Bausch Health Companies Inc (NYSE:BHC) will announce earnings per share (EPS) of $0.88 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Bausch Health Companies’ earnings. The lowest EPS estimate is $0.66 and the highest is $1.01. Bausch Health Companies posted earnings of $0.98 per share during the same quarter last year, which would indicate a negative year over year growth rate of 10.2%. The business is expected to report its next earnings results before the market opens on Wednesday, February 27th.
According to Zacks, analysts expect that Bausch Health Companies will report full-year earnings of $3.81 per share for the current financial year, with EPS estimates ranging from $3.60 to $3.96. For the next financial year, analysts anticipate that the firm will report earnings of $3.86 per share, with EPS estimates ranging from $3.63 to $4.14. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Tuesday, November 6th. The company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.31. The business had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $2.09 billion. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The firm’s revenue was down 3.7% compared to the same quarter last year.
In related news, insider Thomas Appio acquired 25,440 shares of the stock in a transaction dated Friday, December 14th. The shares were purchased at an average cost of $22.96 per share, with a total value of $584,102.40. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 11.54% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of the company. ValueAct Holdings L.P. purchased a new position in shares of Bausch Health Companies during the 3rd quarter valued at about $462,911,000. Vanguard Group Inc purchased a new position in shares of Bausch Health Companies during the 3rd quarter valued at about $223,173,000. Vanguard Group Inc. purchased a new position in shares of Bausch Health Companies during the 3rd quarter valued at about $223,173,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Bausch Health Companies during the 3rd quarter valued at about $214,979,000. Finally, Dimensional Fund Advisors LP purchased a new position in Bausch Health Companies in the 3rd quarter worth approximately $135,538,000. 50.05% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE:BHC traded up $0.06 during trading on Wednesday, reaching $23.09. 3,910,608 shares of the company traded hands, compared to its average volume of 4,340,943. Bausch Health Companies has a 52-week low of $14.44 and a 52-week high of $28.45. The firm has a market cap of $8.08 billion, a PE ratio of 6.03, a price-to-earnings-growth ratio of 0.30 and a beta of 0.14. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.91 and a current ratio of 1.14.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
See Also: Inflation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.